7 results
AACE/ACE 2018 Glycemic Control Algorithm

#AACE #2018 #Glycemic #Diabetes #DM2 #Control #Medication #Algorithm #Endocrinology #PrimaryCare #Management
Control Algorithm ... #AACE #2018 # ... Glycemic #Diabetes ... #DM2 #Control # ... #Endocrinology
Profiles of Antidiabetic Medications - AACE 2018 

#Antidiabetic #Medications #Profiles #SideEffects #Table #DecisionAid #Orals #DM2 #Diabetes
Medications - AACE 2018 ... #SideEffects #Table ... DecisionAid #Orals #DM2 ... #Diabetes #Endocrinology
Diabetes Mellitus Type 2 Inpatient Medication Guide

Classes: Biguanide, Sulfonylurea, TZD, DPP-4 inhibitor, GLP-1 receptor agonist, SGLT2i,
Diabetes Mellitus ... Medication Guide Classes ... #Mellitus #DM2 ... pharmacology #comparison #table ... #endocrinology
SGLT2 Inhibitors 
SGLT2 inhibitors are the newest class of anti-diabetic medications, with the first one (Canagliflozin)
class of anti-diabetic ... being approved in 2013 ... kidney), which causes ... #Medications #DM2 ... #Diabetes #Endocrinology
DPP-4 Inhibitors - Pharmacology Summary
Mechanisms of Action: Inhibits DPP-4 (dipeptidyl peptidase 4), which normally inactivates GLP-1
Januvia) - Once/day tablet ... Onglyza) - Once/day tablet ... not definitively cause ... Pharmacology #Summary #DM2 ... #diabetes #endocrinology
GLP-1 Receptor Agonists - Pharmacology Summary
Mechanisms of Action: Stimulate glucose-dependent insulin release from the pancreas (GLP-1
Ozempic), or daily tablet ... e.g. diarrhea, nausea ... not definitively cause ... Pharmacology #Summary #DM2 ... #diabetes #endocrinology
Preoperative Risk Evaluation

Major Pre-Op Questions:
1. Does the patient have any modifiable risk factors that could be
Insulin dependent DM ... event, follow ACC algorithm ... Diabetes regimen ... PCI/DES ( Levine 2016 ... stroke ( Doherty 2017